Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation

Benjamin J. Lee, Sonia N. Rao, Sheila K. Wang, Jane Y. Lee, Irfana Y. Lakada, Elise M. Gilbert, Viktorija O. Barr, Michael J. Postelnick, Sarah H Sutton, Teresa R Zembower, Maureen K Bolon, Marc H. Scheetz, Nathaniel J. Rhodes*

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Methicillin-susceptible Staphylococcus aureus (MSSA) infections have been successfully treated both with cefazolin and antistaphylococcal penicillins; cefazolin appears effective in MSSA bloodstream infections (BSIs). Thus, our antimicrobial stewardship programme (ASP) implemented a clinical pathway supporting cefazolin use in MSSA-BSIs and restricting oxacillin use to infectious diseases (ID) consultation due to cefazolin's lower cost and more convenient dosing. This before and after quasi-experimental study was conducted to describe the impact on outcomes and process of care measures associated with implementing this pathway among patients with MSSA-BSI. Definitive treatment with cefazolin increased over the study period from 17.3% to 69.8% post-implementation. Clinical failure (5.8% vs. 2.3%; P = 0.62) and in-hospital mortality (3.8% vs. 0%; P = 0.50) were rare pre- and post-implementation. Median hospital length of stay among survivors was similar between pre- and post-implementation periods (P = 0.31). Duration of bacteraemia [median (IQR) 3 (2–4) days vs. 2 (2–3) days; P = 0.002] and rates of re-infection after culture clearance (9.6% vs. 0%; P = 0.06) were reduced post-implementation. Frequency of source control (P = 0.71) and time to source control (P = 0.52) were similar between study periods. Significant increases in ID consultations (33.3% [3/9] vs. 73.3% [22/30]; P = 0.047) and median (IQR) 24-h daily doses [2 (1–3) g vs. 6 (3–6) g; P < 0.01] were seen for patients treated with cefazolin post-implementation. ASPs may find implementation of a similar pathway to be an effective means of improving the care of patients infected with MSSA.

Original languageEnglish (US)
Pages (from-to)650-654
Number of pages5
JournalInternational Journal of Antimicrobial Agents
Volume49
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Cefazolin
Methicillin
Communicable Diseases
Staphylococcus aureus
Referral and Consultation
Infection
Length of Stay
Oxacillin
Critical Pathways
Process Assessment (Health Care)
Bacteremia
Hospital Mortality
Penicillins
Survivors
Patient Care
Costs and Cost Analysis

Keywords

  • Antimicrobial stewardship
  • Bloodstream infection
  • Cefazolin
  • Infectious diseases consultation
  • Methicillin-susceptible Staphylococcus aureus
  • Oxacillin

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Lee, Benjamin J. ; Rao, Sonia N. ; Wang, Sheila K. ; Lee, Jane Y. ; Lakada, Irfana Y. ; Gilbert, Elise M. ; Barr, Viktorija O. ; Postelnick, Michael J. ; Sutton, Sarah H ; Zembower, Teresa R ; Bolon, Maureen K ; Scheetz, Marc H. ; Rhodes, Nathaniel J. / Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation. In: International Journal of Antimicrobial Agents. 2017 ; Vol. 49, No. 5. pp. 650-654.
@article{c1103cfa68d543b1b14ba83594c7784d,
title = "Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation",
abstract = "Methicillin-susceptible Staphylococcus aureus (MSSA) infections have been successfully treated both with cefazolin and antistaphylococcal penicillins; cefazolin appears effective in MSSA bloodstream infections (BSIs). Thus, our antimicrobial stewardship programme (ASP) implemented a clinical pathway supporting cefazolin use in MSSA-BSIs and restricting oxacillin use to infectious diseases (ID) consultation due to cefazolin's lower cost and more convenient dosing. This before and after quasi-experimental study was conducted to describe the impact on outcomes and process of care measures associated with implementing this pathway among patients with MSSA-BSI. Definitive treatment with cefazolin increased over the study period from 17.3{\%} to 69.8{\%} post-implementation. Clinical failure (5.8{\%} vs. 2.3{\%}; P = 0.62) and in-hospital mortality (3.8{\%} vs. 0{\%}; P = 0.50) were rare pre- and post-implementation. Median hospital length of stay among survivors was similar between pre- and post-implementation periods (P = 0.31). Duration of bacteraemia [median (IQR) 3 (2–4) days vs. 2 (2–3) days; P = 0.002] and rates of re-infection after culture clearance (9.6{\%} vs. 0{\%}; P = 0.06) were reduced post-implementation. Frequency of source control (P = 0.71) and time to source control (P = 0.52) were similar between study periods. Significant increases in ID consultations (33.3{\%} [3/9] vs. 73.3{\%} [22/30]; P = 0.047) and median (IQR) 24-h daily doses [2 (1–3) g vs. 6 (3–6) g; P < 0.01] were seen for patients treated with cefazolin post-implementation. ASPs may find implementation of a similar pathway to be an effective means of improving the care of patients infected with MSSA.",
keywords = "Antimicrobial stewardship, Bloodstream infection, Cefazolin, Infectious diseases consultation, Methicillin-susceptible Staphylococcus aureus, Oxacillin",
author = "Lee, {Benjamin J.} and Rao, {Sonia N.} and Wang, {Sheila K.} and Lee, {Jane Y.} and Lakada, {Irfana Y.} and Gilbert, {Elise M.} and Barr, {Viktorija O.} and Postelnick, {Michael J.} and Sutton, {Sarah H} and Zembower, {Teresa R} and Bolon, {Maureen K} and Scheetz, {Marc H.} and Rhodes, {Nathaniel J.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.ijantimicag.2016.12.021",
language = "English (US)",
volume = "49",
pages = "650--654",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "5",

}

Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation. / Lee, Benjamin J.; Rao, Sonia N.; Wang, Sheila K.; Lee, Jane Y.; Lakada, Irfana Y.; Gilbert, Elise M.; Barr, Viktorija O.; Postelnick, Michael J.; Sutton, Sarah H; Zembower, Teresa R; Bolon, Maureen K; Scheetz, Marc H.; Rhodes, Nathaniel J.

In: International Journal of Antimicrobial Agents, Vol. 49, No. 5, 01.05.2017, p. 650-654.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation

AU - Lee, Benjamin J.

AU - Rao, Sonia N.

AU - Wang, Sheila K.

AU - Lee, Jane Y.

AU - Lakada, Irfana Y.

AU - Gilbert, Elise M.

AU - Barr, Viktorija O.

AU - Postelnick, Michael J.

AU - Sutton, Sarah H

AU - Zembower, Teresa R

AU - Bolon, Maureen K

AU - Scheetz, Marc H.

AU - Rhodes, Nathaniel J.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Methicillin-susceptible Staphylococcus aureus (MSSA) infections have been successfully treated both with cefazolin and antistaphylococcal penicillins; cefazolin appears effective in MSSA bloodstream infections (BSIs). Thus, our antimicrobial stewardship programme (ASP) implemented a clinical pathway supporting cefazolin use in MSSA-BSIs and restricting oxacillin use to infectious diseases (ID) consultation due to cefazolin's lower cost and more convenient dosing. This before and after quasi-experimental study was conducted to describe the impact on outcomes and process of care measures associated with implementing this pathway among patients with MSSA-BSI. Definitive treatment with cefazolin increased over the study period from 17.3% to 69.8% post-implementation. Clinical failure (5.8% vs. 2.3%; P = 0.62) and in-hospital mortality (3.8% vs. 0%; P = 0.50) were rare pre- and post-implementation. Median hospital length of stay among survivors was similar between pre- and post-implementation periods (P = 0.31). Duration of bacteraemia [median (IQR) 3 (2–4) days vs. 2 (2–3) days; P = 0.002] and rates of re-infection after culture clearance (9.6% vs. 0%; P = 0.06) were reduced post-implementation. Frequency of source control (P = 0.71) and time to source control (P = 0.52) were similar between study periods. Significant increases in ID consultations (33.3% [3/9] vs. 73.3% [22/30]; P = 0.047) and median (IQR) 24-h daily doses [2 (1–3) g vs. 6 (3–6) g; P < 0.01] were seen for patients treated with cefazolin post-implementation. ASPs may find implementation of a similar pathway to be an effective means of improving the care of patients infected with MSSA.

AB - Methicillin-susceptible Staphylococcus aureus (MSSA) infections have been successfully treated both with cefazolin and antistaphylococcal penicillins; cefazolin appears effective in MSSA bloodstream infections (BSIs). Thus, our antimicrobial stewardship programme (ASP) implemented a clinical pathway supporting cefazolin use in MSSA-BSIs and restricting oxacillin use to infectious diseases (ID) consultation due to cefazolin's lower cost and more convenient dosing. This before and after quasi-experimental study was conducted to describe the impact on outcomes and process of care measures associated with implementing this pathway among patients with MSSA-BSI. Definitive treatment with cefazolin increased over the study period from 17.3% to 69.8% post-implementation. Clinical failure (5.8% vs. 2.3%; P = 0.62) and in-hospital mortality (3.8% vs. 0%; P = 0.50) were rare pre- and post-implementation. Median hospital length of stay among survivors was similar between pre- and post-implementation periods (P = 0.31). Duration of bacteraemia [median (IQR) 3 (2–4) days vs. 2 (2–3) days; P = 0.002] and rates of re-infection after culture clearance (9.6% vs. 0%; P = 0.06) were reduced post-implementation. Frequency of source control (P = 0.71) and time to source control (P = 0.52) were similar between study periods. Significant increases in ID consultations (33.3% [3/9] vs. 73.3% [22/30]; P = 0.047) and median (IQR) 24-h daily doses [2 (1–3) g vs. 6 (3–6) g; P < 0.01] were seen for patients treated with cefazolin post-implementation. ASPs may find implementation of a similar pathway to be an effective means of improving the care of patients infected with MSSA.

KW - Antimicrobial stewardship

KW - Bloodstream infection

KW - Cefazolin

KW - Infectious diseases consultation

KW - Methicillin-susceptible Staphylococcus aureus

KW - Oxacillin

UR - http://www.scopus.com/inward/record.url?scp=85015274762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015274762&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2016.12.021

DO - 10.1016/j.ijantimicag.2016.12.021

M3 - Article

VL - 49

SP - 650

EP - 654

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 5

ER -